Survival and predictors of mortality after completion of TB treatment among people living with HIV: a 5-year analytical cohort

Table 2 Cox proportional hazard model for mortality after TB treatment completion

Characteristics	Unadjusted HR (95%CI)	p-value	Adjusted HR† (95%CI)	p-value
Characteristics at TB treatment completion
Sex
Female	1		1
Male	1.47 (0.90–2.39)	0.122	1.60 (0.93–2.75)	0.093
Age (in years)
16–24	1		–
25–34	0.55 (0.23–1.29)	0.170	–
35–44	0.57 (0.24–1.31)	0.183	–
45+	0.77 (0.31–1.89)	0.571	–
WHO HIV stage
Stage III	1		1
Stage IV	1.85 (1.09–3.16)	0.023	1.58 (0.90–2.78)	0.113
CD4 counts at TB treatment completion (cells/mL)
< 200	2.06 (1.22–3.50)	0.007	1.81 (1.06–3.11)	0.030
≥ 200	1		1
Body mass index (Kg/M²)
< 18	3.79 (2.04–7.05)	< 0.001	–
≥ 18	1		–
ART duration (years)	0.98 (0.87–1.11)	0.752
ART regimen type
First-line	1		–
Other	0.93 (0.38–2.32)	0.882	–
Characteristics at TB diagnosis
Year of TB diagnosis
2008–2012	1		1
2013–2014	0.57 (0.30–1.06)	0.074	0.61 (0.31–1.23)	0.167
Type of TB diagnosis
Microbiological	1		–
Clinical	1.70 (0.93–3.12)	0.084	–
TB history
First episode	1		1
Retreatment	1.97 (1.12–3.45)	0.018	2.12 (1.16–3.85)	0.014
Anatomic site of TB
Pulmonary TB	1		–
Extra-pulmonary TB	1.26 (0.78–2.04)	0.340	–

HR denoted Hazard ratio, CI confidence interval.
†Analysis performed on complete cases (n = 921). Factors which had p- value < 0.2 were included in the adjusted model and removed if p- value > 0.2. Body mass index was removed because it was highly collinear with CD4 counts and TB history.

ISSN: 1471-2334